Anthem Bioscienc

{
  "main_header": {
    "sid": 10039665,
    "name": "Anthem Bioscienc",
    "stock_name": "Anthem Bioscienc",
    "full_name": "Anthem Biosciences Ltd",
    "name_url": "stocks-analysis/anthem-bioscienc",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "774.00",
    "chg": -13.1,
    "chgp": "-1.66%",
    "dir": -1,
    "prev_price": "787.10",
    "mcapval": "43,476.65 Cr",
    "mcap": "Mid Cap",
    "scripcode": 544449,
    "symbol": "ANTHEM",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE0CZ201020",
    "curr_date": "May 20",
    "curr_time": "",
    "bse_nse_vol": "19.48 lacs",
    "exc_status": "Active",
    "traded_date": "May 20, 2026",
    "traded_date_str": "2026 05 20",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anthem-bioscienc-10039665-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-downgraded-to-sell-amid-technical-weakness-and-financial-setbacks-3998462",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_mojoScore_3998462.png",
        "date": "2026-05-19 09:11:12",
        "description": "Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest."
      },
      {
        "title": "Anthem Biosciences Ltd’s Mixed Week: -0.13% Price Change Amid Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltds-mixed-week--013-price-change-amid-technical-shifts-3993727",
        "imagepath": "",
        "date": "2026-05-16 09:05:23",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>11 May:</strong> Technical momentum shifts to mildly bullish amid market outperformance</p>\n                    <p><strong>12 May:</strong> Upgrade to Hold by MarketsMOJO; sideways technical trend emerges</p>\n                    <p><strong>13 May:</strong> Continued technical momentum shift with strong returns</p>\n                    <p><strong>15 May:</strong> Sharp decline of 4.27% on low volume closes the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.784.55</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Clos..."
      },
      {
        "title": "When is the next results date for Anthem Biosciences Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-anthem-biosciences-ltd-3990193",
        "imagepath": "",
        "date": "2026-05-13 23:17:43",
        "description": "The next results date for Anthem Biosciences Ltd is scheduled for 19 May 2026...."
      },
      {
        "title": "Anthem Biosciences Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financials and Improved Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-ltd-upgraded-to-hold-by-marketsmojo-amid-mixed-financials-and-improved-technicals-3988961",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_mojoScore_3988961.png",
        "date": "2026-05-13 08:45:38",
        "description": "Anthem Biosciences Ltd has seen its investment rating upgraded from Sell to Hold as of 12 May 2026, reflecting a combination of improved technical indicators, solid management efficiency, and a cautiously optimistic outlook despite recent quarterly financial setbacks. The mid-cap pharmaceutical company’s Mojo Score now stands at 50.0, signalling a more balanced risk-reward profile for investors."
      },
      {
        "title": "Anthem Biosciences Ltd Sees Technical Momentum Shift Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-sees-technical-momentum-shift-amid-strong-returns-3988792",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_technicaldot_3988792.png",
        "date": "2026-05-13 08:06:25",
        "description": "Anthem Biosciences Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical signals that suggest a mild uptrend after a period of sideways movement. The company’s stock price has gained 2.08% today, closing at ₹800.30, reflecting renewed investor interest amid improving technical indicators."
      },
      {
        "title": "Anthem Biosciences Ltd Technical Momentum Shifts Amid Mixed Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-technical-momentum-shifts-amid-mixed-indicators-3986750",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_technicaldot_3986750.png",
        "date": "2026-05-12 08:09:38",
        "description": "Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a modest day change of -0.07%, the stock’s technical indicators present a complex picture, with bullish signals on weekly MACD and Bollinger Bands contrasting with neutral or bearish cues on monthly charts and volume-based metrics. This article analyses these technical developments in detail, placing them in the context of the stock’s recent price action and relative performance against the Sensex."
      },
      {
        "title": "Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Market Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-ltd-technical-momentum-shifts-to-mildly-bullish-amid-market-outperformance-3984849",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_technicaldot_3984849.png",
        "date": "2026-05-11 08:03:44",
        "description": "Anthem Biosciences Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by a combination of bullish weekly MACD and Bollinger Bands signals, alongside mixed monthly indicators and a recent downgrade in its Mojo Grade from Hold to Sell, reflecting a complex market outlook for this mid-cap pharmaceutical player."
      },
      {
        "title": "Anthem Biosciences Gains 2.68%: Mixed Signals Shape Weekly Momentum",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anthem-biosciences-gains-268-mixed-signals-shape-weekly-momentum-3982596",
        "imagepath": "",
        "date": "2026-05-09 09:02:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> Week opens at Rs.764.10</p>\n                    <p><strong>5 May:</strong> Stock dips 0.42% amid broader market weakness</p>\n                    <p><strong>6 May:</strong> Sharp rebound with 0.99% gain as Sensex rallies</p>\n                    <p><strong>7 May:</strong> Strong 1.37% rise following technical momentum shift</p>\n                    <p><strong>8 May:</strong> MarketsMOJO downgrades stock to Sell; closes at Rs.784.55 (+0.73%)</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.764.10</div></div>\n                    <div class=\"sta..."
      },
      {
        "title": "Anthem Biosciences Downgraded to Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anthem-biosciences-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3980978",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/AnthemBioscienc_mojoScore_3980978.png",
        "date": "2026-05-08 08:24:43",
        "description": "Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 May 2026. This decision follows a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some long-term growth indicators, recent quarterly results and shifting technical trends have raised concerns among analysts, prompting a more cautious stance on the stock."
      }
    ],
    "total": 39,
    "sid": "10039665",
    "stock_news_url": "https://www.marketsmojo.com/news/anthem-biosciences-10039665"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "12-May-2026",
      "details": "Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that an Earnings Conference Call to discuss the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2026 is scheduled on Wednesday May 20 2026 at 11:00 AM IST/ 01:30 AM USA / 06:30 AM UK / 01:30 PM SGT/HKT.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Approve The Standalone And Consolidated Financial Results For The Quarter And Financial Year Ended March 31 2026 And To Consider Recommendation Of Final Dividend",
      "datetime": "12-May-2026",
      "details": "Anthem Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 inter alia to consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended March 31 2026 and to consider the recommendation of final dividend if any for the financial year ended March 31 2026 amongst other routine matters.",
      "source": "BSE"
    },
    {
      "caption": "Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A",
      "datetime": "30-Apr-2026",
      "details": "<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Anthem Biosciences Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>U24233KA2006PLC039703</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>2.96</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Divya Prasad <br/> Designation: Company Secretary and Compliance Officer <br/> EmailId: divya.p@anthembio.com</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Mohammed Gawir Baig <br/> Designation: Chief Financial Officer <br/> EmailId: gawir.b@anthembio.com</div> </div> <div> <br/> Date: 30/04/2026<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Anthem Biosciences Downgraded to Sell Amid Technical Weakness and Financial Setbacks

2026-05-19 09:11:12

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 18 May 2026. This shift reflects a combination of deteriorating technical indicators, disappointing quarterly financial results, and valuation concerns, despite some positive long-term fundamentals and institutional interest.

Read full news article

Anthem Biosciences Ltd’s Mixed Week: -0.13% Price Change Amid Technical Shifts

2026-05-16 09:05:23

Key Events This Week

11 May: Technical momentum shifts to mildly bullish amid market outperformance

12 May: Upgrade to Hold by MarketsMOJO; sideways technical trend emerges

13 May: Continued technical momentum shift with strong returns

15 May: Sharp decline of 4.27% on low volume closes the week

Week Open

Rs.784.55

Week Clos...

Read full news article

When is the next results date for Anthem Biosciences Ltd?

2026-05-13 23:17:43

The next results date for Anthem Biosciences Ltd is scheduled for 19 May 2026....

Read full news article

Anthem Biosciences Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financials and Improved Technicals

2026-05-13 08:45:38

Anthem Biosciences Ltd has seen its investment rating upgraded from Sell to Hold as of 12 May 2026, reflecting a combination of improved technical indicators, solid management efficiency, and a cautiously optimistic outlook despite recent quarterly financial setbacks. The mid-cap pharmaceutical company’s Mojo Score now stands at 50.0, signalling a more balanced risk-reward profile for investors.

Read full news article

Anthem Biosciences Ltd Sees Technical Momentum Shift Amid Strong Returns

2026-05-13 08:06:25

Anthem Biosciences Ltd has demonstrated a notable shift in price momentum, supported by a series of bullish technical signals that suggest a mild uptrend after a period of sideways movement. The company’s stock price has gained 2.08% today, closing at ₹800.30, reflecting renewed investor interest amid improving technical indicators.

Read full news article

Anthem Biosciences Ltd Technical Momentum Shifts Amid Mixed Indicators

2026-05-12 08:09:38

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a modest day change of -0.07%, the stock’s technical indicators present a complex picture, with bullish signals on weekly MACD and Bollinger Bands contrasting with neutral or bearish cues on monthly charts and volume-based metrics. This article analyses these technical developments in detail, placing them in the context of the stock’s recent price action and relative performance against the Sensex.

Read full news article

Anthem Biosciences Ltd Technical Momentum Shifts to Mildly Bullish Amid Market Outperformance

2026-05-11 08:03:44

Anthem Biosciences Ltd has exhibited a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bullish stance. This change is underscored by a combination of bullish weekly MACD and Bollinger Bands signals, alongside mixed monthly indicators and a recent downgrade in its Mojo Grade from Hold to Sell, reflecting a complex market outlook for this mid-cap pharmaceutical player.

Read full news article

Anthem Biosciences Gains 2.68%: Mixed Signals Shape Weekly Momentum

2026-05-09 09:02:46

Key Events This Week

4 May: Week opens at Rs.764.10

5 May: Stock dips 0.42% amid broader market weakness

6 May: Sharp rebound with 0.99% gain as Sensex rallies

7 May: Strong 1.37% rise following technical momentum shift

8 May: MarketsMOJO downgrades stock to Sell; closes at Rs.784.55 (+0.73%)

Week Open

Rs.764.10

Read full news article

Anthem Biosciences Downgraded to Sell Amid Mixed Financial and Technical Signals

2026-05-08 08:24:43

Anthem Biosciences Ltd, a mid-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 May 2026. This decision follows a comprehensive reassessment across four critical parameters: Quality, Valuation, Financial Trend, and Technicals. Despite some long-term growth indicators, recent quarterly results and shifting technical trends have raised concerns among analysts, prompting a more cautious stance on the stock.

Read full news article

View All News